Join to View Full Profile
NKGen Biotech3001 Daimler StSanta Ana, CA 92705
Phone+1 310-310-1992
Dr. Song is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Summary
- I am a board certified radiation oncologist and biotech executive.
Education & Training
University of Chicago/University of Illinois College of Medicine at ChicagoResidency, Radiation Oncology, 1992 - 1996
Cooperman Barnabas Medical CenterInternship, Transitional Year, 1991 - 1992
George Washington University School of Medicine and Health SciencesClass of 1991
Certifications & Licensure
CA State Medical License 2007 - 2026
IL State Medical License 1992 - 2014
NV State Medical License 2005 - 2009
VA State Medical License 1996 - 2008
SC State Medical License 1995 - 1996
American Board of Radiology Radiation Oncology
Clinical Trials
- Safety of SNK01 in Subjects With Pathologically Confirmed Metastatic and/or Unresectable Cancer Refractory to Conventional Therapy Start of enrollment: 2019 Jul 15
Publications & Presentations
PubMed
- Gene and Cell Therapy for Sarcomas: A Review.Sant P Chawla, Skyler S Pang, Darshit Jain, Samantha Jeffrey, Neal S Chawla
Cancers. 2025-03-27 - Treatment of Alzheimer's Disease subjects with expanded non-genetically modified autologous natural killer cells (SNK01): a phase I study.Clemente Humberto Zúñiga, Blanca Isaura Acosta, Rufino Menchaca, Cesar A Amescua, Sean Hong
Alzheimer's Research & Therapy. 2025-02-12 - 4 citationsManagement of radiation-induced mucosal necrosis with photobiomodulation therapy.Joel B. Epstein, Paul Y. Song, Allen S. Ho, Babak Larian, Arash Asher
Supportive Care in Cancer. 2018-05-04
Press Mentions
NKGen Biotech Announces Administration of First Dose of Troculeucel to Frontotemporal Dementia Patient Under FDA-Cleared Compassionate Use ProgramFebruary 21st, 2025- NKGen's Troculeucel Therapy Demonstrates Stability and Cognitive Improvement in AD TrialFebruary 13th, 2025
- NKGen Biotech Announces Publication of Phase 1 Troculeucel Clinical Trial Results for the Treatment of Alzheimer’s DiseaseFebruary 13th, 2025
- Join now to see all
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
